Related Experiment Video

Updated: Aug 13, 2026

Isolation of Sertoli Cells and Peritubular Cells from Rat Testes
11:11

Isolation of Sertoli Cells and Peritubular Cells from Rat Testes

Published on: February 8, 2016

Humoral immune responses to testis antigens in sera from patients with prostate cancer

Luke H Hoeppner1, Jason A Dubovsky, Edward J Dunphy

  • 1Department of Medicine, University of Wisconsin, Madison, WI 53792, USA.

Cancer Immunity
|January 13, 2006
PubMed

Insights

Researchers identified novel prostate cancer antigens, MAD-CT-1 and MAD-CT-2, using a SEREX screening method. These cancer-testis (CT) antigens show promise for developing targeted prostate cancer vaccines with reduced autoimmune risks.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Prostate cancer treatment explores molecularly targeted therapies, including tumor vaccines.
  • Most prostate-specific antigens are not natural targets for immune responses in cancer patients.
  • Cancer-testis (CT) antigens, normally restricted to immune-privileged testis tissue, are expressed in various cancers and are promising targets for immune-based therapies due to tumor restriction and reduced immune tolerance.

Purpose of the Study:

  • To identify potential prostate cancer antigens using the SEREX (Screening of Expressed sequence tags) method.
  • To investigate cancer-testis (CT) antigens as targets for prostate cancer vaccines.
  • To evaluate the feasibility of using sera from prostate cancer patients and a human testis cDNA expression library for antigen discovery.

Main Methods:

  • Utilized the SEREX screening method.
  • Employed sera from prostate cancer patients for screening.
  • Probed a human testis cDNA expression library to identify target antigens.

Main Results:

  • Identified several potential prostate cancer antigens with predominantly testis-specific expression in normal tissues.
  • MAD-CT-1 (protamine 2) and MAD-CT-2 were identified as potential prostate cancer antigens.
  • These antigens were independently identified from different prostate cancer patient samples.

Conclusions:

  • Prostate cancer CT antigens can be identified using the SEREX screening method.
  • MAD-CT-1 and MAD-CT-2 are potential candidates for further investigation as prostate cancer tumor antigens.
  • Targeting these CT antigens may lead to effective prostate cancer vaccines with a lower risk of autoimmune reactions.

More Related Videos

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis06:46

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis

Published on: January 16, 2013

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Testes: Histology01:27

Testes: Histology

A tough, fibrous membrane, the tunica albuginea, covers the testes, extending inward to form fibrous partitions or septa, dividing them into internal compartments called lobules. Each lobule has 1 to 3 tightly coiled seminiferous tubules where sperm production occurs. These tubules merge into a tubular network at the back of the testis, known as the rete testis. It connects to 15 to 20 efferent ductules, leading to the epididymis.
The spermatogenic cells, responsible for producing sperm, are...